Fibnib 150mg Soft Gelatin Capsule contains Nintedanib 150mg, a potent tyrosine kinase inhibitor used primarily in the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC). Nintedanib works by blocking multiple pathways involved in the abnormal growth and proliferation of fibroblasts and cancer cells, thereby slowing disease progression. Fibnib is indicated for patients diagnosed with IPF to reduce lung function decline and improve quality of life. It is also prescribed as part of combination therapy for advanced NSCLC, particularly in cases with adenocarcinoma histology. The soft gelatin capsule formulation ensures ease of swallowing and optimal bioavailability. Patients should take Fibnib exactly as prescribed, typically twice daily with food to minimize gastrointestinal side effects such as diarrhea, nausea, and abdominal pain. Regular monitoring of liver function and blood counts is recommended during treatment to detect potential adverse effects early. Fibnib should be used cautiously in patients with liver impairment and is contraindicated during pregnancy due to potential teratogenic effects. Always consult a healthcare professional before starting or discontinuing Fibnib to ensure safe and effective use tailored to individual health needs.